Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinblastine monotherapy for standard-risk pediatric ALK-positive ALCL
NL-OMON51961Phase 3Not yet recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vinblastine in anaplastic large cell lymphoma (ALCL), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Probability of event-free survival at 3 years. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
vinblastine
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NL-OMON51961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51961.